European Journal of Biomedical and Pharmaceutical Sciences

AN IN VIVO EVALUATION OF THE PHARMACOKINETICS AND BIOAVAILABILITY STUDIES OF BOSWELLIA SERRATA EXTRACT (BOSWEGEX®) IN MALE WISTAR RATS

Vadiraj G. B.*, C. A. Anzar, Joseph M. V., Sundaram R., Prasad C. P. and Bineesh Eranimose

ABSTRACT

In comparison to NSAIDs, boswellic acids (BAs) exhibit elevated tolerance and fewer side effects, all while retaining their effectiveness in addressing inflammation, immunosuppression, and tumors. Sourced from the oleo gum resin of Boswellia serrata Roxb. ex Colebr., these compounds hold promise. Despite their efficacy, BAs' limited solubility results in suboptimal oral absorption. To address this, our study aimed to assess Boswegex®'s pharmacokinetic profile post a single oral dose using LC-MS/MS analysis of serum at varying time points. Our findings revealed a Cmax and Tmax of 10548.19 ng/ml at 6 hours for Boswegex®. Furthermore, the AUC0-24 reached 324403.5 ng.h/ml. Notably, these results underscore Boswegex®'s potential as an innovative treatment avenue, defying concerns over pharmacokinetic interactions. Its heightened absorption and enhanced bioavailability distinguish it, making it a viable alternative for conventional therapeutic applications. Recent developments in Boswegex® highlight its superior absorptive qualities, reinforcing its potential significance as a new standard of care in pain management.

Keywords: Boswegex®, Oral bioavailability, Wistar rats, Tmax and Cmax.